KR970007947B1 - 헤테로사이클릭 스피로 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 - Google Patents

헤테로사이클릭 스피로 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 Download PDF

Info

Publication number
KR970007947B1
KR970007947B1 KR1019880012963A KR880012963A KR970007947B1 KR 970007947 B1 KR970007947 B1 KR 970007947B1 KR 1019880012963 A KR1019880012963 A KR 1019880012963A KR 880012963 A KR880012963 A KR 880012963A KR 970007947 B1 KR970007947 B1 KR 970007947B1
Authority
KR
South Korea
Prior art keywords
group
compound
ring
atom
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019880012963A
Other languages
English (en)
Korean (ko)
Other versions
KR890006649A (ko
Inventor
신이찌 쯔까모토
히토시 나가오까
신지 우스다
마사토미 하라다
토시나리 타무라
Original Assignee
야마노우찌세이야꾸 가부시끼가이샤
모리오까 시게오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 야마노우찌세이야꾸 가부시끼가이샤, 모리오까 시게오 filed Critical 야마노우찌세이야꾸 가부시끼가이샤
Publication of KR890006649A publication Critical patent/KR890006649A/ko
Application granted granted Critical
Publication of KR970007947B1 publication Critical patent/KR970007947B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
KR1019880012963A 1987-10-05 1988-10-05 헤테로사이클릭 스피로 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 Expired - Fee Related KR970007947B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP?252104/1987? 1987-10-05
JP25210487 1987-10-05
JP252104/1987 1987-10-05
JP?286297/1987? 1987-11-12
JP28629787 1987-11-12
JP286297/1987 1987-11-12
JP84327/1988 1988-04-05
JP?84327/1988? 1988-04-05
JP8432788 1988-04-05

Publications (2)

Publication Number Publication Date
KR890006649A KR890006649A (ko) 1989-06-15
KR970007947B1 true KR970007947B1 (ko) 1997-05-19

Family

ID=27304516

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880012963A Expired - Fee Related KR970007947B1 (ko) 1987-10-05 1988-10-05 헤테로사이클릭 스피로 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물

Country Status (14)

Country Link
US (4) US4940795A (enExample)
EP (1) EP0311313B1 (enExample)
JP (1) JPH0236183A (enExample)
KR (1) KR970007947B1 (enExample)
CN (1) CN1036653C (enExample)
AT (1) ATE122353T1 (enExample)
AU (1) AU621559B2 (enExample)
CA (1) CA1337817C (enExample)
DE (1) DE3853758T2 (enExample)
DK (1) DK554288A (enExample)
ES (1) ES2074441T3 (enExample)
GR (1) GR3016995T3 (enExample)
HU (1) HU211687A9 (enExample)
NO (1) NO171109C (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5412096A (en) * 1987-10-05 1995-05-02 Yamanouchi Pharmaceutical Co., Ltd. Hydrochloride salts of heterocyclic spiro compounds
ES2074441T3 (es) * 1987-10-05 1995-09-16 Yamanouchi Pharma Co Ltd Compuestos espiro heterociclicos y su preparacion.
US5075317A (en) * 1989-06-21 1991-12-24 Fisons Corporation Spirofurane derivatives
US5594000A (en) * 1989-06-21 1997-01-14 Astra Ab Spirofurane derivatives
US5852029A (en) * 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5407938A (en) * 1990-04-10 1995-04-18 Israel Institute For Biological Research Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines)
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
IE914238A1 (en) * 1990-12-19 1992-07-01 Fisons Corp Novel spirofurane derivatives
ATE168114T1 (de) * 1991-05-15 1998-07-15 Yamanouchi Pharma Co Ltd (-)-(s)-2,8-dimethyl-3-methylen-1-oxa-8- azaspiro(4,5)decan l-tartrat
EP0681571B1 (en) * 1993-01-28 1998-07-29 Merck & Co. Inc. Spiro-substituted azacycles as tachykinin receptor antagonists
US5688806A (en) * 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
JP2983141B2 (ja) * 1993-10-06 1999-11-29 株式会社三和化学研究所 新規化合物及び該化合物を有効成分とする脳機能改善剤
NZ500643A (en) 1997-05-30 2001-12-21 Neurosearch As Spiro-quinuclidine derivatives and their use in treating conditions responsive to nicotinic ACh receptor modulators
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
EP1209974A2 (en) * 1999-08-13 2002-06-05 Aventis CropScience GmbH Heterocyclic spiro compounds as pesticides
AU2001253597A1 (en) * 2000-04-12 2001-10-30 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
JP2003063964A (ja) * 2001-08-28 2003-03-05 Senju Pharmaceut Co Ltd ドライアイまたはドライアイを伴なう疾病の予防治療剤
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
JPWO2007013661A1 (ja) * 2005-07-26 2009-02-12 千寿製薬株式会社 眼科用経皮吸収型製剤
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275095A3 (en) * 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
ITMI20061279A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
EP2076288A2 (en) * 2006-09-22 2009-07-08 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
EP2322168A1 (en) 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
US9034891B2 (en) 2009-01-26 2015-05-19 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
RU2506266C2 (ru) 2009-01-26 2014-02-10 Израэл Инститьют Фо Байолоджикал Рисерч Бициклические гетероциклические спиросоединения
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2014011917A2 (en) 2012-07-13 2014-01-16 Pain Therapeutics, Inc. A method of inhibiting tau phosphorylation
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム
CN115124545B (zh) * 2022-08-31 2023-01-03 南京远淑医药科技有限公司 一种促性腺激素释放激素受体拮抗剂中间体的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3305556A (en) * 1962-11-23 1967-02-21 Pfizer & Co C Novel hypoglycemic agents
NL124853C (enExample) * 1963-07-19
SU335944A1 (ru) * 1970-12-15 1976-01-25 Научно-исследовательский институт химии Саратовского государственного университета им.Н.Г.Чернышевского Способ получени соединений р да 1-окса6-азаспиро(4,4)нонана
US3784551A (en) * 1971-07-08 1974-01-08 Yoshitomi Pharmaceutical 2-oxo-1,4-dioxa-8-azaspiro (4.5) decanes and related compounds
GB1301254A (enExample) * 1971-07-08 1972-12-29
US3839273A (en) * 1971-11-13 1974-10-01 Sankyo Co N-substituted piperidine derivatives, process for preparing the same and their use as stabilizers
SU434735A1 (ru) * 1972-03-01 1975-12-15 Научно-исследовательский институт химии Саратовского государственного университета им.Н.Г.Чернышевского Способ получени 7-метил-(или 2,7диметил)-2-метокси- -пропионитрил1-окса-6-азаспиро-(4,4)-нонана
SU465399A1 (ru) * 1973-07-19 1975-03-30 Научно-исследовательский институт химии при Саратовском государственном университете им.Н.Г.Чернышевского Способ получени натриевых солей 2-метокси- -карбоксиэтил-1-окса6-азаспиро-(4,4)-нонана
IL48452A (en) * 1975-11-11 1979-07-25 Purdue Frederick Co Spiro (1,3-dioxolane-4,3') quinuclidines,their preparationand pharmaceutical compositions comprising them
US4321379A (en) * 1981-01-28 1982-03-23 American Cyanamid Company 4-Aryl-1-oxa-8-azaspiro[4,5]dec-3-en-2-ones
SU1002294A1 (ru) * 1981-08-14 1983-03-07 Ордена Трудового Красного Знамени Институт Тонкой Органической Химии Им.А.Л.Мнджояна 2,2-Диалкил-3-тиа-8-азаспиро/5,5/ундеканы
EP0189370A3 (de) * 1985-01-16 1988-01-27 Sandoz Ag Spiro-dioxolane, -dithiolane und -oxothiolane
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US4981858A (en) * 1987-08-13 1991-01-01 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Optical isomers
ES2074441T3 (es) * 1987-10-05 1995-09-16 Yamanouchi Pharma Co Ltd Compuestos espiro heterociclicos y su preparacion.
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents

Also Published As

Publication number Publication date
EP0311313B1 (en) 1995-05-10
HU211687A9 (en) 1995-12-28
AU2344988A (en) 1989-04-06
DK554288D0 (da) 1988-10-04
US5041549A (en) 1991-08-20
NO884406L (no) 1989-04-06
EP0311313A2 (en) 1989-04-12
JPH0236183A (ja) 1990-02-06
ES2074441T3 (es) 1995-09-16
US4940795A (en) 1990-07-10
KR890006649A (ko) 1989-06-15
CA1337817C (en) 1995-12-26
DE3853758T2 (de) 1995-09-07
CN1036653C (zh) 1997-12-10
DE3853758D1 (de) 1995-06-14
NO171109B (no) 1992-10-19
GR3016995T3 (en) 1995-11-30
CN1033629A (zh) 1989-07-05
ATE122353T1 (de) 1995-05-15
DK554288A (da) 1989-05-26
NO171109C (no) 1993-01-27
EP0311313A3 (en) 1990-12-05
US4996210A (en) 1991-02-26
USRE34653E (en) 1994-07-05
JPH0544948B2 (enExample) 1993-07-07
AU621559B2 (en) 1992-03-19
NO884406D0 (no) 1988-10-04

Similar Documents

Publication Publication Date Title
KR970007947B1 (ko) 헤테로사이클릭 스피로 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
DE60129210T2 (de) Zyklische amid-derivate
US5466689A (en) Morpholine derivatives and their use
EP0088903A2 (en) 1,4-Dihydropyridine-3,5-dicarboxylic acid ester derivatives
US4879300A (en) Novel piperidine derivatives
US4735944A (en) Spiro-dioxolanes, -dithiolanes and -oxothiolanes, and their use in mental therapy
US5412096A (en) Hydrochloride salts of heterocyclic spiro compounds
EP0411912B1 (en) Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders
US4992436A (en) Spiro-azabicyclic muscarinic agonists
US4977175A (en) 4,5,6,7-tetrahydrobenzimidazole derivatives as 5HT3 -antagonists
US5075317A (en) Spirofurane derivatives
US6258829B1 (en) Cycloalka[b]pyridine-3-carbonylguanidine derivatives, process for producing the same, and drugs containing the same
EP0670313A1 (en) Spiro compounds, their production and use
WO1999038864A1 (en) Oxazole derivatives as serotonin-1a receptor agonists
AU2006316706B2 (en) Isoquinoline and benzo[H]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine H3 receptor
US4031223A (en) Trifluoromethylthio derivatives of cyproheptadine
JPH02164882A (ja) スピロ化合物及びその中間体
US5077295A (en) Antipsychoic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)buytl bridged bicycle imides
AU607966B2 (en) Pilocarpine derivatives
KR0128975B1 (ko) 9-아실아미노-테트라히드로아크리딘 유도체 및 그 유도체를 활성 성분으로 포함하는 기억력 촉진제
US4010161A (en) Piperazinoethyl-N-(2,3-dimethyl-5-oxo-1-phenyl-3Δ-pyrazolin-4-yl)carbamates
EP0057536A1 (en) Pharmaceutically active compounds
KR820001835B1 (ko) 4-아미노-2-피페리디노퀴나졸린 유도체의 제조방법
RU2128178C1 (ru) Пиперидинилзамещенные метаноантрацены и их фармацевтически приемлемые соли, фармацевтическая композиция на их основе и способы их получения
JPH02247183A (ja) ヘテロ環スピロ化合物

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20001021

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20001021

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301